Last $146.06 USD
Change Today +3.06 / 2.14%
Volume 2.0M
VRX On Other Exchanges
Symbol
Exchange
Toronto
New York
Frankfurt
As of 8:04 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Key Developments

Valeant Pharmaceuticals International Announces Redemption of USD 445.0 Million Aggregate Principal Amount of Its Outstanding 6.875% Senior Notes Due 2018

Valeant Pharmaceuticals International announced that it will redeem USD 445.0 million aggregate principal amount of its outstanding 6.875% Senior Notes due 2018, CUSIP Nos. 91911XAN4, U9098VAF9 (the "Notes") on December 29, 2014 and has mailed an irrevocable notice of redemption for the Notes. Following the redemption, approximately USD 500 million aggregate principal amount of the Notes will remain outstanding.

Valeant Pharmaceuticals International, Inc. Announces FDA Approval of ONEXTON Gel for the Treatment of Acne Vulgaris

Valeant Pharmaceuticals International, Inc. announced that it has received approval from the Food and Drug Administration (FDA) for ONEXTON Gel (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75%, for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 and older. ONEXTON(TM) Gel has a favorable cutaneous tolerability profile and contains no surfactants, alcohol or preservatives. ONEXTON Gel has been studied extensively prior to its approval.

Valeant Pharmaceuticals International, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 02:20 PM

Valeant Pharmaceuticals International, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 02:20 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Valeant Pharmaceuticals International Announces FDA and Health Canada Approval to Market Ideal Implant for Cosmetic Breast Augmentation

Valeant Pharmaceuticals International, Inc. announced the receipt of approval from the U.S. Food and Drug Administration and Health Canada to market the IDEAL IMPLANT(r) Saline-filled Breast Implant for use in primary breast augmentation or replacement of existing augmentation implants. The FDA approval of the IDEAL IMPLANT was based on an extensive review of various studies and data including a U.S. clinical trial that began in 2009 with 45 plastic surgeons and 502 women, who underwent breast augmentation or replacement of augmentation implants. The clinical trial is on-going and will continue to provide follow-up data through 2020.

Valeant Pharmaceuticals Seeks Acquisitions

Valeant Pharmaceuticals International, Inc. (TSX:VRX) is looking for acquisition opportunities. Michael Pearson, Chairman and Chief Executive Officer of Valeant. "We will remain focused on delivering strong organic results and evaluating acquisition opportunities as we always have: prudently, in a disciplined manner, and in the best interests of our shareholders."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $146.06 USD +3.06

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $265.39 USD +1.64
Astellas Pharma Inc ¥1,703 JPY +47.50
Mylan Inc/PA $57.51 USD +0.68
Perrigo Co PLC $168.14 USD +3.29
Shire PLC 4,629 GBp -53.00
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings 96.4x
Price/Sales 5.9x
Price/Book 9.3x
Price/Cash Flow 25.2x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.